| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| J0178 |
Injection, aflibercept, 1 mg |
8,782 |
7,973 |
$14.10M |
| J2778 |
Injection, ranibizumab, 0.1 mg |
4,247 |
3,970 |
$4.85M |
| 67028 |
Intravitreal injection of a pharmacologic agent |
45,644 |
40,823 |
$2.80M |
| 92134 |
|
71,698 |
63,397 |
$1.44M |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
27,187 |
24,336 |
$1.16M |
| Q5128 |
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg |
1,455 |
1,269 |
$1.06M |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
15,351 |
13,920 |
$929K |
| J9035 |
Injection, bevacizumab, 10 mg |
19,806 |
17,427 |
$929K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
2,088 |
1,933 |
$173K |
| 92250 |
|
5,728 |
4,748 |
$107K |
| 92235 |
|
1,570 |
1,473 |
$91K |
| J3590 |
Unclassified biologics |
68 |
49 |
$36K |
| 99233 |
Prolong inpt eval add15 m |
459 |
280 |
$30K |
| 92004 |
Ophthalmological services: medical examination and evaluation, comprehensive, new patient |
298 |
283 |
$28K |
| 67228 |
|
116 |
95 |
$19K |
| 76512 |
|
69 |
65 |
$2K |
| 92020 |
|
118 |
115 |
$2K |
| 1036F |
|
41 |
38 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
41 |
38 |
$0.00 |
| G8397 |
Dilated macular or fundus exam performed, including documentation of the presence or absence of macular edema and level of severity of retinopathy |
14 |
13 |
$0.00 |
| G8482 |
Influenza immunization administered or previously received |
39 |
35 |
$0.00 |
| 2024F |
|
17 |
16 |
$0.00 |
| G9744 |
Patient not eligible due to active diagnosis of hypertension |
15 |
15 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
45 |
40 |
$0.00 |
| 4040F |
|
52 |
46 |
$0.00 |
| 2026F |
|
19 |
17 |
$0.00 |
| 5010F |
|
14 |
13 |
$0.00 |
| 2022F |
|
17 |
16 |
$0.00 |